On Friday, Following Stocks were among the “Top 100 Losers” of U.S. Stock Market: Cheetah Mobile Inc. (NYSE:CMCM), MiMedx Group, Inc. (NASDAQ:MDXG), Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), Quantum Corporation (NYSE:QTM)

Cheetah Mobile Inc. (NYSE:CMCM), with shares declined -5.90%, closed at $17.53.

MiMedx Group, Inc. (NASDAQ:MDXG), with shares dropped -2.99%, settled at $9.89.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), with shares dipped -5.64%, and closed at $4.18.

Quantum Corporation (NYSE:QTM), plummeted -2.92%, and closed at $1.66.

Latest NEWS regarding these Stocks are depicted underneath:

Cheetah Mobile Inc. (NYSE:CMCM)

Cheetah Mobile Inc. (CMCM), a leading mobile Internet corporation that provides mission critical applications to assist make the Internet and mobile experience speedier, simpler, and safer for users worldwide, declared its unaudited financial results for the fourth quarter and fiscal year ended December 31, 2014.

Fourth Quarter 2014 Financial Highlights:

• Total proceeds raised by 118.8% year-over-year and 23.0% quarter-over-quarter to RMB588.9 million (US$94.9 million).
• Mobile proceeds raised by 610.2% year-over-year and 96.6% quarter-over-quarter to RMB 222.1 million (US$35.8 million), led by a noteworthy growth of mobile advertising proceeds. Mobile accounted for 38% of total proceeds.
• Overseas proceeds raised by 156.5% quarter-over-quarter to RMB139.1 million (US$22.4 million), led by a noteworthy ramp-up of mobile advertising proceeds in the overseas market. Overseas accounted for 24% of total proceeds and 63% of mobile proceeds.
• GAAP net revenue attributable to Cheetah Mobile shareholders raised by 23.8% year-over-year and 780.6% quarter-over-quarter to RMB32.2 million (US$5.2 million).
• Non-GAAP net revenue attributable to Cheetah Mobile shareholders2 (which excludes share-based compensation expenses) raised by 132.4% year-over-year and 37.3% quarter-over-quarter to RMB82.7 million (US$13.3 million).

Fourth Quarter 2014 Key Operating Metrics:

• Total global mobile user installations raised by 26.3% quarter-over-quarter to 1,089.1 million as of December 31, 2014.
• Mobile monthly active users (“Mobile MAUs”) raised by 137.9% year-over-year to 395.4 million as of December 31, 2014. Mobile MAUs from overseas markets were 69.0% of total mobile MAUs in December 2014.

Cheetah Mobile Inc. operates a platform that offer mission critical applications for its users and global content distribution channels for its business partners in the People’s Republic of China.

MiMedx Group, Inc. (NASDAQ:MDXG)

MiMedx Group, Inc. (MDXG), the leading regenerative medicine corporation utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, declared that Deborah Dean, Executive Vice President, and Frank Burrows, Vice President, will represent the Corporation at the 3rd Annual Regen Med Investor Day in New York, New York. The presentation will be conducted “investor conference” style, with a 5-minute introduction by the presenter, followed by a 10 minute ‘fireside chat’ talk aboution on stage with a leading research analyst. The MiMedx timeslot is planned for Wednesday, March 25th, at 10:50 a.m. EDT, at the Metropolitan Club.

Organized by the Alliance for Regenerative Medicine (ARM), in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. The event comprises clinical and commercial experts who will be on-hand to address specific questions regarding the outlook for the industry, in addition to offer insight into how regenerative medicine products could influence the standard of care in key therapeutic areas. The program will comprise talks by key opinion leaders in the industry, life science investment experts and analysts, in addition to presentations by more than 30 leading companies from across the globe.

MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. “Innovations in Regenerative Biomaterials” is the framework behind our mission to give physicians products and tissues to assist the body heal itself.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)

Formerly on March 12, Idera Pharmaceuticals, Inc. (IDRA), stated its financial and operational results for the fourth quarter and year ended December 31, 2014.

“2014 was a year of transformation for Idera, as we focused our corporation on oncology and rare diseases,” stated Vincent Milano, Chief Executive Officer of Idera Pharmaceuticals. “During 2014, we commenced two Phase 1/2 clinical trials of IMO-8400 for the treatment of certain B-cell lymphomas in which the MYD88 L265P oncogenic mutation is present and also conducted pre-clinical studies of our Toll-like receptor, or TLR9 agonists as immune therapies for the treatment of cancer. In addition, we selected dermatomyositis and Duchenne muscular dystrophy, or DMD, as the first non-cancer rare diseases for which we plan to develop IMO-8400. We also expanded our leadership team and raised our capital resources, with the aim of delivering hope for the patients we aim to serve and creating value for our shareholders.”

“For 2015 we look forward to start delivering clinical results commencing in the fourth quarter from our Phase 1/2 clinical trial of IMO-8400 in Waldenstrom’s macroglobulinemia. In addition, we are now working to rapidly advance our targeted immuno-oncology program into the clinic and also expect to commence clinical development in our rare diseases program by initiating a Phase 2 clinical trial of IMO-8400 in dermatomyositis and DMD by the end of 2015 and early 2016, respectively. We also plan to complete our Phase 1 healthy volunteer trial with IMO-9200 during the year. Finally, we are planning to conduct disease model studies and start IND-enabling development programs in each of the first two disease indications selected for further development in our gene silencing oligonucleotide, or GSO, program in the second half of 2015.”

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical corporation, focuses on the discovery, development, and commercialization of novel therapeutics for oncology and rare diseases in the United States. It uses two proprietary drug discovery technology platforms to design and develop drug candidates, counting toll-like receptor targeting technology and gene silencing oligonucleotide (GSO) technology.

Quantum Corporation (NYSE:QTM)

Quantum Corporation (QTM), declared that China’s National Animation Industry Park (NAIP) in Tianjin, the country’s largest animation center, is using Quantum StorNext® shared storage as the foundation for its 4K postproduction workflows. The animation park turned to Quantum when its legacy system was unable to handle the performance and capacity requirements of its new 4K projects, and the StorNext solution has enabled NAIP to raise the efficiency of its workflows by 60 to 80 percent.

NAIP’s StorNext storage solution — which encompasses a metadata appliance, a gateway appliance and disk storage — allows all of the facility’s creative professionals to work on content simultaneously in a high-performance, high-capacity environment. They can now handle 4K content with 48MB of data volume per frame and replay an entire film at a rate of 24 frames per second, native, when performing quality control.

Quantum Corporation provides scale-out storage, archive, and data protection solutions for small businesses to major enterprises in the Americas, Europe, and the Asia Pacific.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.